Comparison of Liver Recovery After Sleeve Gastrectomy and Roux-en-Y-Gastric Bypass

Sophia M.-T. Schmitz¹ · Andreas Kroh¹ · Alexander Koch² · Jonathan F. Brozat² · Christine Stier³ · Ulf P. Neumann¹,⁴ · Tom F. Ulmer¹,⁴ · Patrick H. Alizai¹

Received: 10 November 2020 / Revised: 21 March 2021 / Accepted: 25 March 2021 / Published online: 4 April 2021
© The Author(s) 2021

Abstract

Background Nonalcoholic fatty liver disease (NAFLD) is a common condition in patients with obesity. Bariatric surgery has often been proposed as a viable treatment option, but the ideal surgical procedure remains unclear. Inconsistently, reports on postoperative deterioration of liver function put further doubt on which technique to apply. Aim of this study was to assess the impact of Roux-en-Y-gastric bypass (RYGB) and sleeve gastrectomy (SG) on the postoperative recovery of liver function.

Methods A total of 175 patients with obesity that underwent bariatric surgery in our institution were included in this prospective cohort study. BMI, laboratory values, and liver function capacity (using LiMAx) were assessed preoperatively and at 6 and 12 months postoperatively. Generalized linear model (GLM) was performed to determine variables influencing liver function capacity after the operation.

Results Prior to operations, 64% of patients presented with a diminished liver function capacity, as measured by LiMAx test. Liver function capacity significantly recovered after 12 months in the SG group (300 μg/kg/h preop vs. 367 μg/kg/h postop) but not in the RYGB group (306 μg/kg/h preop vs. 349 μg/kg/h). Preoperative factors impeding liver function recovery included type 2 diabetes mellitus (T2DM), weight, male sex, AST/thrombocyte ratio (APRI), and gamma-glutamyltransferase (GGT).

Conclusion Bariatric surgery, especially sleeve gastrectomy, leads to an improvement of liver function. However, in some patients with T2DM, higher preoperative weight and male sex postoperative deterioration of liver function capacity may occur.

Keywords NAFLD · Liver function · LiMAx · Sleeve gastrectomy · Roux-en-Y-gastric bypass · Bariatric surgery

Sophia M.-T. Schmitz
sopschmitz@ukaachen.de
Andreas Kroh
akroh@ukaachen.de
Alexander Koch
akoch@ukaachen.de
Jonathan F. Brozat
jbrozat@ukaachen.de
Christine Stier
Christine.Stier@Sana.de
Ulf P. Neumann
uneumann@ukaachen.de
Tom F. Ulmer
fulmer@ukaachen.de
Patrick H. Alizai
palizai@ukaachen.de

1 Department of General-, Visceral- and Transplantation Surgery, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany
2 Department of Gastroenterology, Digestive Diseases and Intensive Care Medicine, RWTH Aachen University Hospital, Pauwelsstr. 30, 52074 Aachen, Germany
3 Obesity Center NRW, Sana Kliniken, Hürth, Germany
4 Department of Surgery, Maastricht University Medical Center, P. Debyelaan 25, 6229 HX Maastricht, The Netherlands
Introduction

Nonalcoholic fatty liver disease (NAFLD) is a progressive condition affecting a large number of patients worldwide, with an estimated prevalence of 25% [1]. Obesity is found to be an underlying condition for NAFLD frequently and can be considered as the hepatic manifestation of the metabolic syndrome [2]. The rising incidence of NAFLD is closely linked to the rising incidence of obesity [1, 3]. Prevalence of NAFLD in patients undergoing bariatric surgery has been described in up to 95% of cases [4]. Weight loss improves NAFLD and reduces its likelihood of progression to nonalcoholic steatohepatitis (NASH) and cirrhosis [5–10]. The positive impact of bariatric surgery on altitude of liver enzyme elevation has been assessed in a large prospective intervention study [11]. Histologically, grade of NAFLD ameliorates after bariatric surgery, as measured by NAFLD activity score (NAS) [6, 9, 12–14]. Even liver fibrosis can be resolved after bariatric surgery in some cases [6, 9, 14–17]. However, there are also reports of acute liver failure or worsening of preexisting liver injury following bariatric surgery [6, 18, 19].

As of today, the right surgical procedure as a treatment option for patients with NAFLD is subject to intense discussions. Some studies suggest sleeve gastrectomy (SG) and Roux-en-Y-gastric bypass (RYGB) to be of equal effectiveness in amelioration of NAFLD [10, 12, 13], while others favor either RYGB [6, 17, 20] or SG [5, 16, 21]. Thus, the aim of this study was to compare postoperative recovery of liver function between RYGB and SG and to assess risk factors for potential deterioration of liver function capacity.

Material and Methods

Study Design

The present study was conducted between 2013 and 2019 as a prospective cohort study at RWTH Aachen University Hospital.

Indication for surgery was defined through interdisciplinary board as follows: body mass indices (BMI) of > 40 kg/m² or > 35 kg/m² with weight-related comorbidities. Patients with a BMI < 50 kg/m² were submitted to intensive preoperative weight loss therapy prior to operation. Patients with < 15% reduction in body weight were then transferred to surgery. Operative procedure (sleeve gastrectomy or Roux-en-Y-gastric bypass) was determined according to individual conditions (comorbidities and previous abdominal operations) and patients’ preferences. In patients with a history of diabetes or esophagogastric reflux disease, Roux-en-Y-gastric bypass (RYGB) was preferred over sleeve gastrectomy (SG). In some cases with high abdominal fat masses, SG had to be performed due to anatomical causes. RYGB was performed with an antecolic Roux-en-Y-configuration with a biliopancreatic limb of 50–75 cm (proximal RYGB). Patients under 18 years of age or with a history of alcohol consumption (> 20 g/day) were excluded. Diagnosis of diabetes was made on the basis of HbA1C levels over 6.5%, fasting plasma glucose > 126 mg/dl, or oral glucose tolerance test 140 to 199 mg/dl. Informed consent was obtained from all individual participants included in the study. All patients receive specific dietetic recommendations after surgery. Recommendations include balanced meals with small portions and a diet low in calories, sweets, and fat with a high protein intake. After both procedures, a multivitamin supplementation is recommended and after RYGB, an additional calcium supplementation. Further supplementations are recommended according to blood test results. Medication for diabetes of hypertension is reduced or discontinued as soon as possible. Participants of this study underwent the non-invasive LiMAX liver function capacity test and blood collection prior to operation, as well as 6 and 12 months after surgery. All data, including clinical data such as age, weight, and height, were stored in a secured, pseudonymized database. Percent excess BMI loss (%EBMIL) was calculated according to Deitel et al. [22].

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Ethical approval was granted by our local Ethics Committee.

Laboratory Tests

Blood samples were drawn after overnight fasting the day before the operation. Biochemical parameters were determined at the Institute of Clinical Chemistry of our University Hospital. Normal ranges of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are < 50 U/L; for gamma-glutamyltransferase (GGT) < 40 U/L. Normal range of platelet (PLT) was defined as 150–400/nL, while overall percentage of glycated hemoglobin (HbA1c) was considered non-pathological between 4 and 6%. APRI was calculated by dividing AST through platelets [23, 24].

Liver Function Capacity

LiMAX test was used for non-invasive measurement of liver function capacity. It is based on metabolism of 13C-methacetin by the hepatic cytochrome P450 1A2 system (CYP1A2). The test is performed via intravenous injection of 2 mg/kg body weight 13C-methacetin (Euriso-top, Saint-Aubin Cedex, France). Metabolization of 13C-methacetin into acetaminophen and 13CO2 is measured by examination of exhaled 13CO2. Metabolization is measured through real-time point-of-care (POC) breath sampling with a laser-based
nondispersive isotope-selective infrared spectroscope (FLIP2, Humedics, Berlin, Germany). The set up allows for analysis of functional capacity of the CYP1A2 system (hereafter referred to as liver functioning capacity). A physiological liver function capacity is indicated by values of > 315 μg/kg/h.

Statistical Analysis

Statistical analysis was performed using Graph Pad Prism® v7, IBM SPSS® v25, and Microsoft Excel®. Outliers with a value higher or lower than two times the standard deviation (SD) of the mean were excluded from further analyses. Values are presented as mean and standard error of the mean (SEM) or median and interquartile range (IQR) unless stated otherwise. One-way ANOVA and the two-sided t-test were used to compare means. Comparison of surgical procedure and impairment of liver function capacity was done with chi-square test. Generalized linear model (GLM) was used for multivariate analysis. The β coefficients in the GLM were used to assess the effect of the independent variables. Higher coefficients resemble higher association. A p < 0.05 was considered statistically significant.

Results

Patient Characteristics

A total of 175 patients were included in this study; 50% of patients (n = 88) underwent SG and 50% (n = 87) underwent RYGB. Mean BMI prior to operation was 52.7 kg/m² (SEM 0.64) and 73% of patients (n = 129) were female. There was no statistically significant difference in BMI prior to operation for patients that underwent SG when compared to patients that underwent RYGB (p = 0.87). Patients in the SG group were more likely to be male (37% vs. 15% in the RYGB group) and suffer from hypertension (63% vs. 51%) and type 2 diabetes mellitus (T2DM) (38% vs. 24%). For further details on the study population, see Table 1. Overall mean BMI decreased significantly after 6 months (39.7 kg/m², SEM 0.56) and 12 months (35.7 kg/m², SEM 0.55); 12 month postoperative %EMBIL was higher after RYGB when compared to SG (66%, SEM 2.1 vs. 57%, SEM 2.4; p = 0.013) (see Table 2).

Preoperative Liver Function

Prior to surgery, mean LiMax value was 303 μg/kg/h (SEM 8.9). A LiMax value prior to operation could be obtained from 162 patients, n = 80 patients in the RYGB group and n = 82 in the SG group. There was no difference between the SG and the RYGB groups (p = 0.807); 103 patients (64%) had a score below the normal value of 315 μg/kg/h. Mean APRI prior to operation in all patients was 0.099 (SEM 0.003) with no statistically significant difference between SG and RYGB groups (p = 0.328) (see Table 1). APRI could be obtained from 164 patients prior to operation.

Postoperative Liver Function

A LiMax test could be obtained from 91 patients after 6 months (47 patients in the RYGB group and 44 patients in the SG group) and 75 patients after 12 months (30 patients in the RYGB group and 45 patients in the SG group). After 1 year, LiMax values improved significantly only in the SG group (300 μg/kg/h preop vs. 367 μg/kg/h postop, p = 0.021), while values in the RYGB group showed no statistically significant improvement (306 μg/kg/h preop vs. 349 μg/kg/h postop, p = 0.45) (Fig. 1). A weak but significant inverse correlation between %EBMIL and percentual change of liver function capacity could be observed at 6 months (Y = −0.70 × X + 48.23, R² = 0.10, p = 0.002), but not at 12 months following bariatric surgery (Y = 0.11 × X + 23.76, R² = 0.002, p = 0.714). Six months after surgery, 47% of patients showed an impaired liver function capacity, while 12 months after surgery, 64% of patients had an impaired liver function capacity. Chi-square test revealed no difference between patients after SG and RYGB (p = 0.930 and 0.280, respectively).

Table 1  Study population prior to operation

|          | Total | SG   | RYBG |
|----------|-------|------|------|
| n        | 175   | 88   | 87   |
| Female   | 129 (73%) | 55 (63%) | 74 (85%) | 0.003* |
| BMI (kg/m²) | 52.7 (0.64) | 53.5 (1.01) | 51.8 (0.78) | 0.087 |
| LiMax (μg/kg/h) | 302.8 (8.9) | 300.1 (12.0) | 305.6 (13.2) | 0.756 |
| Abnormal liver function test results (LiMax < 315 μg/kg/h) | 103 (64%) | 51 (62%) | 52 (65%) | 0.807 |
| APRI     | 0.099 (0.003) | 0.1 (0.005) | 0.097 (0.004) | 0.328 |
| T2DM     | 54 (31%) | 33 (38%) | 21 (24%) | 0.036* |
| Arterial hypertension | 99 (66%) | 55 (63%) | 44 (51%) | 0.046* |
APRI could be calculated in 142 patients after 6 months (76 patients in the RYGB group and 66 patients in the SG group) and 122 patients after 12 months (65 patients in the RYGB group and 57 patients in the SG group). APRI index showed a similar pattern as LiMAx with improvement after 12 months in the SG group (0.1 preop vs. 0.081 postop, \( p = 0.007 \)) but not in the RYGB group (0.097 preop vs. 0.086 postop, \( p = 0.67 \)) (Fig. 2).

Factors Influencing Liver Function Capacity

Generalized linear model was performed for liver function capacity measured by LiMAx at 6 and 12 months postoperatively. Covariates included preoperative LiMAx, age, APRI, BMI, and body weight, as well as laboratory values HbA1c, AST, ALT, and GGT. Fixed factors included were sex, T2DM, and hypertension.

At 6 months after surgery, T2DM was associated with a 71-unit decrease in LiMAx in patients after RYGB (\( \beta = -70.7, SE 33.4, p = 0.034 \)) but not after SG (\( \beta = 2.37, SE 59.2, p = 0.97 \)). For patients undergoing RYGB, each kilogram of weight prior to operation was associated with a 2-unit decrease in LiMAx (\( \beta = -2, SE 0.9, p = 0.027 \)). Of all laboratory values taken into account, only GGT revealed a significant association to liver function capacity after 6 months (\( \beta = -1.1, SE 0.5, p = 0.03 \)). For patients undergoing SG, only preoperative GGT revealed a significant association with LiMAx after 6 months with an increase of 2.2 units for each unit of GGT (\( \beta = 2.2, SE 0.8, p = 0.006 \)). For a summary of all variables, see Table 3.

At 12 months after surgery, preoperative weight was associated with a decreased liver function capacity in patients after RYGB (\( \beta = -3.1, SE 1.5, p = 0.043 \)). After SG, male gender was associated with a 140-unit decreased liver function capacity compared to female gender (\( \beta = -140.3, SE 51.4, p = 0.006 \)). LiMAx and APRI prior to operation were both associated with an increased liver function capacity after 12 months in patients (\( \beta = 0.6, SE 0.1, p = 0.000 \) and \( \beta = 1241.8, SE 395, p = 0.002 \), respectively). For a summary of all variables after 12 months, please refer to Table 4.

Discussion

Bariatric surgery presents an accepted treatment modality for NAFLD [6, 11, 12, 17, 25, 26]. However, evidence on the modality of choice with regard to NAFLD (SG or RYGB) is sparse and a statement regarding the operative approach is lacking in the guidelines [26, 27]. While some studies suggest superiority for one of the operative procedures, others advocate their equality [12, 25]. A paramount concern about bariatric surgery in patients with chronic liver disease is potential worsening of preexisting liver conditions, underlining the importance of NAFLD assessment prior to surgery [19, 26, 28].
An explanation can be that while most patients remained similar succeeding both procedures (see Table 2). Patients presenting with impaired liver function capacity and showed a positive trend after RYGB, the percentage of aspartate transaminase, NAFLD activity score, and NAFLD RYGB and SG as correlated through alanine transaminase, going sleeve gastrectomy, a recently published meta-analysis these results of enhanced function capacity in patients under-2). Our data concurs closely with Billeter et al., who found improved liver function following SG in comparison to RYGB in patients with T2DM with regard to early postoperative liver function capacity in patients after SG but not after RYGB (see Table 3). In contrast, 6 month liver function capacity for SG patients seemed only affected by GGT, showing a slight, albeit, positive impact. %EBMIL was not associated with a decreased liver function capacity after 12 months neither in the SG nor in the RYGB group but revealed a trend towards a decreased liver function capacity in both groups after 6 months (see Table 4). Additionally, %EBMIL revealed a negative correlation with percentage change in LiMAx value after 6 months. Taken together, these findings indicate that rapid weight loss in the first 6 months after surgery might be associated with an initial worsening of liver function. Supporting this, a recent randomized controlled trial by Kalinowski et al. found a deterioration in liver function 1 month after surgery that was resolved after 12 months [19]. In this study, patients with NAFLD were at a higher risk of postoperative impaired liver function after RYGB than patients after SG. Likewise, Nickel et al. described an increased APRI shortly (1 month) after bariatric surgery [20]. However, they also found significant improvement of APRI 12 months after surgery with no difference between SG and RYGB [20]. Correspondingly, Yeo et al. report on a positive correlation of weight loss and amelioration of NAFLD after 12 months but not after 6 months. Mean BMI prior to operation in this study was 42 kg/m² and hence much lower than in ours (mean BMI 53 kg/m²). One factor influencing early postoperative liver function capacity in patients after bariatric surgery is the development of portomesenteric vein thrombosis [35]. This rare but severe condition appears to evolve more frequently after SG than after RYGB, most likely due to locally diminished blood flow after dissection of the greater curvature [36, 37].

Our findings furthermore suggest an influence of T2DM on regeneration of liver function after metabolic surgery. This is of high clinical importance due to the high prevalence of diabetes in patients with obesity. In patients who underwent RYGB, presence of T2DM was associated with a decrease in LiMAx at 6 months after surgery (see Table 3). For SG, patients with T2DM showed no significant decrease in LiMAx after 6 months. Our data indicate a slight advantage of SG in patients with T2DM with regard to early postoperative liver function capacity. In another matched pair study, SG improves after surgery, other patients might suffer from impairment of liver function. Furthermore, even patients with improved liver function capacity after surgery might still suffer from impaired liver function due to severely impaired initial liver function capacity. This ultimately leads to the important question, which patients present with a constant or worsening liver function capacity after bariatric surgery.

There is growing evidence that major changes in liver function and volume occur within the first 6 months after surgery [19, 20]. In our study, generalized linear model revealed significant influences for T2DM, preoperative weight, preoperative LiMAx, APRI, and GGT on liver function capacity after 6 months in patients after RYGB (see Table 3). In contrast, 6 month liver function capacity for SG patients seemed only affected by GGT, showing a slight, albeit, positive impact.
has also been described superior to RYGB in terms of ameliorating liver function in patients with T2DM [21].

Other factors influencing postoperative liver function capacity include APRI, GGT, and preoperative LiMAx. In particular for RYGB, we found an association of higher GGT levels with lower postoperative liver function capacity values after 6 months. Surprisingly, in SG, GGT levels showed a positive impact on liver function capacity after 6 months (see Table 3).

These findings have some clinical implications. Liver function shows a significant improvement after SG but not after RYGB. In terms of preexisting liver diseases, SG is preferred in patients with manifest cirrhosis due to a lower complication profile by some authors [5, 29, 38–40]. Furthermore, SG has been described as being more cost-effective than RYGB in patients with NASH cirrhosis [41]. While RYGB has recently been proposed as superior in EWL for patients that suffer from super obesity [42], two-stage RYGB with an initial sleeve gastrectomy followed by RYGB yields comparable results [43]. As higher weight was associated with a decreased liver function capacity after 6 months in patients with RYGB but not SG, our data encourage choosing SG as a first step with possible step-up to RYGB after initial weight loss in patients with high preoperative weight. To sum up, in patients with high preoperative weight and underlying preexisting liver disease, SG can be considered less harmful than RYGB. Furthermore, our findings reveal risk factors for impaired liver function capacity and indicate which patients might benefit from a closer monitoring of liver function postoperatively.

### Table 3 Multivariate analysis of factors influencing liver function capacity 6 months after surgery

| Operative procedure | Independent factors | Estimate, β | SE | 95% Confidence interval | p-value |
|---------------------|---------------------|-------------|----|------------------------|---------|
| RYGB                | Intercept           | 285.3       | 172.4 | -52.5–623.27 | 0.098 |
|                     | Sex                 | 6.2         | 42.9 | -77.8–90.2     | 0.885 |
|                     | T2DM                | -70.7       | 33.4 | 5.2–136.1     | 0.034* |
|                     | Arterial hypertension | -10.8     | 26.8 | -63.3–41.8    | 0.688 |
|                     | Age                 | 0.6         | 1.1  | -1.6–2.8       | 0.597 |
|                     | Weight              | -1.9        | 0.9  | 3.8 to -0.22   | 0.027* |
|                     | BMI                 | 1.0         | 2.7  | -4.2–6.2      | 0.710 |
|                     | LiMAx               | 0.5         | 0.1  | 0.3–0.7       | 0.000* |
|                     | APRI                | 660.9       | 269.0 | 133.6–1188.2  | 0.014* |
|                     | AST                 | 1.6         | 2.1  | -2.6–5.8       | 0.462 |
|                     | ALT                 | -1.7        | 1.1  | -3.8–0.5      | 0.137 |
|                     | GGT                 | -1.1        | 0.5  | 2.1 to -0.1    | 0.030* |
|                     | HbA1c               | 31.0        | 24.3 | -16.7–78.6    | 0.203 |
|                     | %EBMIL 6 months after surgery | -1.6    | 0.8  | 3.3–0.0       | 0.056 |
| SG                  | Intercept           | 746.2       | 332.2 | 95.2–1397.2  | 0.025* |
|                     | Sex                 | 128.3       | 70.5 | -9.9–266.6   | 0.069 |
|                     | T2DM                | -2.4        | 59.2 | -113.7–118.5  | 0.968 |
|                     | Arterial hypertension | 23.4      | 48.0 | -70.7–117.5   | 0.626 |
|                     | Age                 | -6.1        | 3.1  | -12.3–0.1     | 0.052 |
|                     | Weight              | -2.1        | 2.0  | -6.0–1.8      | 0.291 |
|                     | BMI                 | -1.4        | 4.5  | -10.2–7.5     | 0.763 |
|                     | LiMAx               | 0.2         | 0.2  | -0.2–0.7      | 0.350 |
|                     | APRI                | -950.5      | 569.0 | -2065.8–164.7 | 0.095 |
|                     | AST                 | -3.6        | 3.8  | -11.2–4.0     | 0.351 |
|                     | ALT                 | 4.3         | 2.6  | -0.8–9.4      | 0.096 |
|                     | GGT                 | 2.2         | 0.8  | 0.6–3.8       | 0.006* |
|                     | HbA1c               | 27.5        | 40.2 | -51.2–106.2   | 0.494 |
|                     | %EBMIL 6 months after surgery | -2.0   | 1.1  | -4.2–0.3      | 0.082 |

Abbreviations: BMI, body mass index; LiMAx, liver function capacity test LiMAx; SG, sleeve gastrectomy; RYGB, Roux-en-Y-gastric bypass; SE, standard error; T2DM, type 2 diabetes mellitus; APRI, aspartate aminotransferase (AST) to platelet ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HbA1c, glycated hemoglobin; %EBMIL, percentage excess BMI loss; * statistically significant using generalized linear model.
There are some limitations to be mentioned. One limitation is the high number of missing data for LiMAX after 6 and 12 months which might be due to the fact that LiMAX test is not available everywhere. However, we could obtain APRI values from almost all patients and could show a similar tendency. The results were not correlated to histological findings of liver biopsies. Furthermore, shear wave elastography and magnetic resonance elastography have recently been gaining importance in the diagnosis of fibrosis in NAFLD and might be a valuable option for preoperative evaluation of liver function \[44, 45\]. Another limitation is the relatively small number of patients included and the lack of randomization. Notwithstanding these limitations, as guidelines for the selection of the operative procedure in NAFLD are lacking, this study provides encouraging results towards patient selection and monitoring of patients at risk for worsening of liver function after bariatric surgery.

**Conclusion**

In patients undergoing bariatric surgery, liver function improved significantly 12 months after sleeve gastrectomy, but not after Roux-en-Y-gastric bypass. We found a negative correlation between weight loss and amelioration of liver function. Factors associated with a decreased liver function capacity included type 2 diabetes mellitus, high preoperative

---

**Table 4** Multivariate analysis of factors influencing liver function capacity 12 months after surgery

| Operative procedure | Independent factors | Estimate, β | SE | 95% Confidence interval | p-value |
|---------------------|---------------------|-------------|----|------------------------|---------|
| RYGB                | Intercept           | 184.7       | 428.3 | −654.6−1024.1          | 0.666   |
|                     | Sex                 | 93.5        | 60.2 | −24.6−211.6            | 0.121   |
|                     | T2DM                | −37.2       | 60.6 | −156.0−81.5            | 0.539   |
|                     | Arterial hypertension | −45.7   | 60.6 | −164.5−73.1            | 0.450   |
|                     | Age                 | −3.0        | 2.4  | −7.8−1.7               | 0.211   |
|                     | Weight              | −3.1        | 1.5  | −6.2−0.1               | 0.043*  |
|                     | BMI                 | 7.4         | 5.5  | −3.4−18.2              | 0.182   |
|                     | LiMAX               | 0.4         | 0.2  | 0.1−0.7                | 0.007*  |
|                     | APRI                | −262.3      | 717.7 | −1669.1−1144.4         | 0.715   |
|                     | AST                 | −1.4        | 3.6  | −8.4−5.6               | 0.699   |
|                     | ALT                 | −0.1        | 2.4  | −4.8−4.5               | 0.950   |
|                     | GGT                 | −1.1        | 1.0  | −3.1−1.0               | 0.301   |
|                     | HbA1c               | 51.3        | 48.1 | −43.0−145.5            | 0.286   |
|                     | %EBMIL 12 months after surgery | 0.3 | 3.2 | −6.0−6.6 | 0.935 |
| SG                  | Intercept           | 98.1        | 210.5 | −314.4−510.6          | 0.641   |
|                     | Sex                 | −140.3      | 51.4 | −241.0−39.6            | 0.006*  |
|                     | T2DM                | −6.5        | 38.0 | −80.8−67.9             | 0.864   |
|                     | Arterial hypertension | −1.4   | 40.0 | −79.9−77.1            | 0.972   |
|                     | Age                 | 3.5         | 2.1  | −0.740−7.7             | 0.106   |
|                     | Weight              | 1.1         | 1.3  | −1.5−3.7               | 0.406   |
|                     | BMI                 | 1.3         | 3.0  | −4.5−7.1               | 0.659   |
|                     | LiMAX               | 0.6         | 0.1  | 0.3−0.8                | 0.000*  |
|                     | APRI                | 1241.8      | 395.0 | 467.6−2016.1          | 0.002*  |
|                     | AST                 | −1.4        | 2.8  | −6.9−4.187             | 0.632   |
|                     | ALT                 | −3.6        | 2.3  | −8.1−1.0               | 0.123   |
|                     | GGT                 | 1.1         | 0.8  | −4.4−2.6               | 0.165   |
|                     | HbA1c               | −50.2       | 25.4 | −99.9−0.4              | 0.049*  |
|                     | %EBMIL 12 months after surgery | 0.8 | 1.3 | −1.7−3.3 | 0.514 |

Abbreviations: BMI, body mass index; LiMAX, liver function capacity test; SG, sleeve gastrectomy; RYGB, Roux-en-Y-gastric bypass; SE, standard error; T2DM, type 2 diabetes mellitus; APRI, aspartate aminotransferase (AST) to platelet ratio; AST, aspartate aminotransferase; ALT, alanine aminotransferase; GGT, gamma-glutamyl transferase; HbA1c, glycated hemoglobin; %EBMIL, percentage excess BMI loss; * statistically significant using generalized linear model
weight, impaired APRI, elevated GGT, and male sex. Therefore, patients with these constellations should receive monitoring of liver function after the operation.

Data indicated as \( n \) (percent) or mean (SEM). Abbreviations: 
- BMI, body mass index 
- LiMAX, liver function capacity test 
- SG, sleeve gastrectomy 
- RYGB, Roux-en-Y-gastric bypass 
- SEM, standard error of the mean 
- APRI, aspartate aminotransferase (AST) to platelet ratio 
- \( T2DM \), type 2 diabetes mellitus 

Data indicated as \( n \) (percent) or mean (SEM). Abbreviations: 
- BMI, body mass index 
- LiMAX, liver function capacity test 
- SG, sleeve gastrectomy 
- RYGB, Roux-en-Y-gastric bypass 
- SEM, standard error of the mean 
- APRI, aspartate aminotransferase (AST) to platelet ratio; * statistically significant using chi-square test

Impact of bariatric surgery on hepatic function and predictors of liver steatosis and fibrosis. Obes Surg. 2020;30(8):2945–41.

References

1. Younossi ZM. Non-alcoholic fatty liver disease—a global public health perspective. J Hepatol. 2019;70(3):531–44.
2. Otgonsuren M, Stepanova M, Gerber L, et al. Anthropometric and clinical factors associated with mortality in subjects with nonalcoholic fatty liver disease. Dig Dis Sci. 2013;58(4):1132–40.
3. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11–20.
4. Souto KP, Meinhardt NG, Ramos MJ, et al. Nonalcoholic fatty liver disease in patients with different baseline glucose status undergoing bariatric surgery: analysis of intraoperative liver biopsies and literature review. Surg Obes Relat Dis. 2018;14(1):66–73.
5. Waits SA, Sheetz KH, Ghafari AA. Considering bariatric surgery in patients with nonalcoholic steatohepatitis—worth the risk. JAMA Netw Open. 2019;2(2):e190053.
6. Lee Y, Doumouras AG, Yu J, et al. Complete resolution of nonalcoholic fatty liver disease after bariatric surgery: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(6):1040–60. e11
7. Mathurin P, Hollebecque A, Armalsteen L, et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology. 2009;137(2):532–40.
8. Alizai PH, Wendl J, Roeth AA, et al. Functional liver recovery after bariatric surgery—a prospective cohort study with the LiMAX test. Obes Surg. 2015;25(11):2047–53.
9. Mummadi RR, Kasturi KS, Chennareddygi S, et al. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2008;6(12):1396–402.
10. Wirth KM, Sheka AC, Kisy S, et al. Bariatric surgery is associated with decreased progression of nonalcoholic fatty liver disease to cirrhosis: a retrospective cohort analysis. Ann Surg. 2020;272(1):32–9.
11. Burza MA, Romeo S, Kotronen A, et al. Long-term effect of bariatric surgery on liver enzymes in the Swedish Obese Subjects (SOS) study. PLoS One. 2013;8(3):e60495.
12. Baldwin D, Chennakesavalu M, Gangemi A. Systematic review and meta-analysis of Roux-en-Y gastric bypass against laparoscopic sleeve gastrectomy for amelioration of NAFLD using four criteria. Surg Obes Relat Dis. 2019;15(12):2123–30.
13. von Schonfels W, Beckmann JH, Ahrens M, et al. Histologic improvement of NAFLD in patients with obesity after bariatric surgery based on standardized NAS (NAFLD activity score). Surg Obes Relat Dis. 2018;14(10):1607–16.
14. Salmon MA, Salmon AA, Abdelsalam A, et al. Laparoscopic sleeve gastrectomy on the horizon as a promising treatment modality for NAFLD. Obes Surg. 2020;30(1):87–95.
15. Froylich D, Corelles R, Daigle C, et al. Effect of Roux-en-Y gastric bypass and sleeve gastrectomy on nonalcoholic fatty liver disease: a comparative study. Surg Obes Relat Dis. 2016;12(1):127–31.
16. Koh ZJ, Salgaonkar HP, Lee WJ, et al. Improvement in nonalcoholic fatty liver disease score correlates with weight loss in obese patients undergoing laparoscopic sleeve gastrectomy: a two-centre study from an Asian cohort. Obes Surg. 2019;29(3):862–8.
17. Borges-Canha M, Neves JS, Mendonca F, et al. The impact of bariatric surgery on hepatic function and predictors of liver steatosis and fibrosis. Obes Surg. 2020;30(8):2945–41.
18. Vespaiai-Gentilucci U, Vorini F, Carotti S, et al. Hepatic complications of bariatric surgery: the reverse side of the coin. Acta Gastro-Entero Belg. 2017;80(4):505–13.
19. Kalinowski P, Paluszskiewicz R, Ziarikiewicz-Wroblewska B, et al. Liver function in patients with nonalcoholic fatty liver disease randomized to Roux-en-Y gastric bypass versus sleeve gastrectomy: a secondary analysis of a randomized clinical trial. Ann Surg. 2017;266(5):738–45.
20. Nickel F, Tapking C, Benner L, et al. Bariatric surgery as an efficient treatment for non-alcoholic fatty liver disease in a prospective study with 1-year follow-up: BariScan study. Obes Surg. 2018;28(5):1342–50.
21. Billiter AT, Senft J, Gotthardt D, et al. Combined non-alcoholic fatty liver disease and type 2 diabetes mellitus: sleeve gastrectomy or gastric bypass?—a controlled matched pair study of 34 patients. Obes Surg. 2016;26(8):1867–74.
22. Deitel M, Gaw lat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007;17(5):565–8.
23. Shin WG, Park SH, Jun SY, et al. Simple tests to predict hepatic fibrosis in nonalcoholic chronic liver diseases. Gut Liver. 2007;1(2):145–50.
24. Schwimmer JB, Behling C, Angeles JE, et al. Magnetic resonance elastography measured shear stiffness as a biomarker of fibrosis in pediatric nonalcoholic fatty liver disease. Hepatology. 2017;66(5):1474–85.
25. Cherla DV, Rodriguez NA, Vangoitsenhoven R, Singh T, Mehta N, McCullough AJ, et al. Impact of sleeve gastrectomy and Roux-en-Y gastric bypass on biopsy-proven non-alcoholic fatty liver disease. Surg Endosc 2019.

26. Perysinakis I, Pappis HC, Margaris E. Current controversies in metabolic surgery for nonalcoholic fatty liver disease. Obes Surg. 2019;29(3):1058–67.

27. Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 2012;55(6):2005–23.

28. Mahawar KK, Parmar C, Graham Y, et al. Monitoring of liver function tests after Roux-en-Y gastric bypass: an examination of evidence base. Obes Surg. 2016;26(10):2516–22.

29. Mumtaz K, Lipshultz H, Jalil S, et al. Bariatric surgery in patients with cirrhosis: careful patient and surgery-type selection is key to improving outcomes. Obes Surg. 2020;30(9):3444–52.

30. Schmitz SM, Kroh A, Ulmer TF, et al. Evaluation of NAFLD and fibrosis in obese patients—a comparison of histological and clinical scoring systems. BMC Gastroenterol. 2020;20(1):254.

31. Alizai PH, Lurje I, Kroh A, et al. Noninvasive evaluation of liver function in morbidly obese patients. Gastroenterol Res Pract. 2019;2019:4307462.

32. Stockmann M, Lock JF, Malinowski M, et al. The LiMAx test: a new liver function test for predicting postoperative outcome in liver surgery. HPB (Oxford). 2010;12(2):139–46.

33. Lock JF, Malinowski M, Seehofer D, et al. Function and volume recovery after partial hepatectomy: influence of preoperative liver function, residual liver volume, and obesity. Langenbeck's Arch Surg. 2012;397(8):1297–304.

34. Praveen Raj P, Gomes RM, Kumar S, et al. The effect of surgically induced weight loss on nonalcoholic fatty liver disease in morbidly obese Indians: “NASHOST” prospective observational trial. Surg Obes Relat Dis. 2015;11(6):1315–22.

35. James AW, Rabl C, Westphalen AC, et al. Portalomesenteric venous thrombosis after laparoscopic surgery: a systematic literature review. Arch Surg. 2009;144(6):520–6.

36. Moon RC, Ghanem M, Teixeira AF, et al. Assessing risk factors, presentation, and management of portomesenteric vein thrombosis after sleeve gastrectomy: a multicenter case-control study. Surg Obes Relat Dis. 2018;14(4):478–83.

37. Goitein D, Matter I, Raziel A, et al. Portomesenteric thrombosis following laparoscopic bariatric surgery: incidence, patterns of clinical presentation, and etiology in a bariatric patient population. JAMA Surg. 2013;148(4):340–6.

38. Garcia-Sesma A, Calvo J, Manrique A, et al. Morbidly obese patients awaiting liver transplantation-sleeve gastrectomy: safety and efficacy from a liver transplant unit experience. Transplant Proc. 2019;51(1):33–7.

39. Jan A, Narwaria M, Mahawar KK. A systematic review of bariatric surgery in patients with liver cirrhosis. Obes Surg. 2015;25(8):1518–26.

40. Goh GB, Schauer PR, McCullough AJ. Considerations for bariatric surgery in patients with cirrhosis. World J Gastroenterol. 2018;24(28):3112–9.

41. Klebanoff MJ, Corey KE, Samur S, et al. Cost-effectiveness analysis of bariatric surgery for patients with nonalcoholic steatohepatitis cirrhosis. JAMA Netw Open. 2019;2(2):e190047.

42. Samuel N, Jalal Q, Gupta A, et al. Mid-term bariatric surgery outcomes for obese patients: does weight matter? Ann R Coll Surg Engl. 2020;102(1):54–61.

43. Diaz-Tobarra M, Cassinello Fernandez N, Jorda Gomez P, et al. One-stage vs two-stage laparoscopic Roux-en-Y gastric bypass in obese patients with body mass index >55 kg/m²: 5-year follow up. Obes Surg. 2017;27(4):955–60.

44. Xiao G, Zhu S, Xiao X, et al. Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: a meta-analysis. Hepatology. 2017;66(5):1486–501.

45. Tapper EB, Loomba R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD. Nat Rev Gastroenterol Hepatol. 2018;15(5):274–82.

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.